Breast cancer resistance protein (BCRP/ABCG2)
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
15694832
DOI
10.1016/j.biocel.2004.11.004
PII: S1357-2725(04)00398-X
Knihovny.cz E-resources
- MeSH
- ATP Binding Cassette Transporter, Subfamily G, Member 2 MeSH
- ATP-Binding Cassette Transporters chemistry metabolism physiology MeSH
- Polymorphism, Single Nucleotide MeSH
- Humans MeSH
- Mutation MeSH
- Neoplasm Proteins chemistry metabolism physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- ATP Binding Cassette Transporter, Subfamily G, Member 2 MeSH
- ATP-Binding Cassette Transporters MeSH
- ABCG2 protein, human MeSH Browser
- Neoplasm Proteins MeSH
Breast cancer resistance protein (BCRP) was identified 7 years ago as the most recent member of ABC drug efflux membrane transporters. It is a 655 amino acid peptide with an ability to extrude a wide variety of chemical compounds from the cells. Today, it is considered as one of three major transporters causing drug resistance in mammalian cells. It is also distributed in epithelia involved in drug disposition with major role in the placenta, liver and intestine. In addition, BCRP is responsible for the "side population" phenotype of stem cells and seems to play a significant role in protection against hypoxia. BCRP inhibitors are currently searched for to overcome drug resistance and to improve the pharmacokinetics, mainly intestinal absorption, of substrate drugs. Mutant BCRP has also been used as a selectable marker in stem cell gene therapy applications.
References provided by Crossref.org
